Rheumatology, Vol 38, 407-410, Copyright © 1999 by British Society for Rheumatology
A So, AM Chamot, V Peclat and JC Gerster
OBJECTIVE: Metalloproteinases (MMP) play an important role in the
remodelling of the extracellular matrix. However, evidence that they are
responsible for tissue damage in pathological situations remains
circumstantial. Stromelysin (MMP-3) production is increased in rheumatoid
arthritis (RA), and has been proposed as a marker of joint damage. The
relevance of serum levels of MMP-3 to erosions in RA was studied. METHODS:
Fifty-three patients with active RA of > 5 yr duration and with
available X-rays were stratified according to disease duration. Hand X-rays
were scored for erosions. Patients were then classified into upper and
lower quartiles. Serum MMP-3 levels were compared between these two groups.
RESULTS: No significant differences in serum MMP-3 were seen between high
and low eroders. A statistically significant correlation was observed
between sMMP-3 and erthyrocyte sedimentation rate and C-reactive protein.
CONCLUSIONS: Serum MMP-3 is not an independent marker of joint damage, but
is correlated with systemic inflammation. Its precise role in joint damage
in RA remains to be elucidated.
ORIGINAL PAPERS
Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status
Rheumatology Service, University Hospital of Lausanne, Switzerland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. J. Green, A. K. S. Gough, J. Devlin, J. Smith, P. Astin, D. Taylor, and P. Emery Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis Rheumatology, January 1, 2003; 42(1): 83 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A A den Broeder, L A B Joosten, T Saxne, D Heinegard, H Fenner, A M M Miltenburg, W L H Frasa, L J van Tits, W A Buurman, P L C M van Riel, et al. Long term anti-tumour necrosis factor {alpha} monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Ann Rheum Dis, April 1, 2002; 61(4): 311 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Klimiuk, S. Sierakowski, R. Latosiewicz, B. Cylwik, J. Skowronski, and J. Chwiecko Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis Rheumatology, January 1, 2002; 41(1): 78 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Stix, T. Kahne, K. Sletten, J. Raynes, A. Roessner, and C. Rocken Proteolysis of AA Amyloid Fibril Proteins by Matrix Metalloproteinases-1, -2, and -3 Am. J. Pathol., August 1, 2001; 159(2): 561 - 570. [Abstract] [Full Text]
|
|
|
|
|
|
C. Ribbens, B. Andre, O. Kaye, M.-J. Kaiser, V. Bonnet, J.-M. Jaspar, D. de Groote, N. Franchimont, and M. G. Malaise Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not Rheumatology, December 1, 2000; 39(12): 1357 - 1365. [Abstract] [Full Text] [PDF]
|
|